• 1
    Purcell RH. The discovery of hepatitis viruses. Gastroenterology 1993; 104: 95563.
  • 2
    Merican I, Guan R, Amarapuka D et al. Chronic hepatitis B virus infection in Asian countries. J. Gastroenterol. Hepatol. 2000; 15: 135661.
  • 3
    Yang BM, Paik SW, Hahn OS, Yi DH, Choi MS, Payne S. Economic evaluation of the societal costs of hepatitis B in South Korea. J. Gastroenterol. Hepatol. 2001; 16: 3018.
  • 4
    Health and Welfare Statistics Association. Trend of national public health. Kosei-No-Shihyo 1997; 44: 4334.
  • 5
    Law MG, Roberts SK, Dore GJ, Kaldor JM. Primary hepatocellular carcinoma in Australia, 1978–1997. increasing incidence and mortality. Med. J. Aust. 2000; 173: 4035.
  • 6
    The Public Health Association of Australia. Hepatitis B vaccination. Policy statements section 11 – Infectious and transmissible diseases. Cited 11 June 2003. Available from URL:
  • 7
    Asia–Pacific Expert Committee on Hepatitis B Management Meeting, 5–6 April 2002, Sydney Australia.
  • 8
    Dai Z, Qi G. Viral Hepatitis in China: Seroepidemiological Survey in Chinese Population (Part One: 1992–1995). Beijing: Science and Technology Archives Press, 1997; 3959.
  • 9
    Department of Health, Hong Kong Special Administrative Region. Surveillance of Viral Hepatitis in Hong Kong – 2001 Update Report. Hong Kong: Department of Health, Hong Kong Special Administrative Region (SAR), December 2002.
  • 10
    Thyagarajan SP, Hari R, Murugavel KG, Joyee AG, Balakrishnan P, Rajendran P. Prevalence of hepatitis B virus infection in general population of India. Indian J. Gastroenterol. 2000; 19 (Suppl. 3): L03.
  • 11
    Kant L, Arora NK. Transmission of hepatitis B virus in children: Indian scenario. Indian J. Gastroenterol. 2000; 19 (Suppl. 3): L01.
  • 12
    Amarapurkar DN, Baijal R, Kulshrestha PP, Agal S, Chakraborty MR, Pramanik SS. Profile of hepatitis B e antigen-negative chronic hepatitis B. Indian J. Gastroenterol. 2002; 21: 99101.
  • 13
    Yap SF, Wong PW, Chen YC, Rosmawati M. The frequency of pre-core mutations in chronic hepatitis B infection: a study of Malaysian subjects. Southeast Asian J. Trop. Med. Public Health 2002; 33: 1029.
  • 14
    Aga Khan University, Karachi, Pakistan. 5% of Pakistani population has hepatitis B. News & Events: A seminar on hepatitis B, April 9 2001. Cited 11 June 2003. Available from URL:
  • 15
    James L, Fong CW, Foong BH et al. Hepatitis B seroprevalence study 1999. Singapore Med. J. 2001; 42: 4204.
  • 16
    Guan R. Hepatitis B virus infection in Singapore. Gut 1996; 38 (Suppl. 2): S1317.
  • 17
    Department of Health, The Executive Yuan, Taiwan, Republic of China. Control of communicable diseases. Section 4, Hepatitis Control, 2000. Cited 16 April 2003. Available from URL:
  • 18
    Huo TI, Wu JC, Lin RY, Sheng WY, Chang FY, Lee SD. Decreasing hepatitis D virus infection in Taiwan: an analysis of contributory factors. J. Gastroenterol. Hepatol. 1997; 12: 7476.
  • 19
    Andre F. Hepatitis B epidemiology in Asia, the middle east and Africa. Vaccine 2000; 18 (Suppl. 1): S202.
  • 20
    World Health Organization. Hepatitis B. Combating Communicable Diseases, 2002. Cited 17 April 2003. Available from URL:
  • 21
    John TJ, Abraham P. Hepatitis B in India: a review of disease epidemiology. Indian Pediatr. 2001; 38: 131825.
  • 22
    Ishida T, Takao S, Settheetham-Ishida W, Tiwawech D. Prevalence of hepatitis B and C virus infection in rural ethnic populations of Northern Thailand. J. Clin. Virol. 2002; 24: 315.
  • 23
    Funk ML, Rosenberg DM, Lok ASF. World-wide epidemiology of HBeAg-negative chronic hepatitis B and associated precore and core promoter variants. J. Viral. Hepat. 2002; 9: 5261.
  • 24
    Papatheodoridis GV, Hadziyannis SJ. Diagnosis and management of pre-core mutant chronic hepatitis B. J. Viral. Hepat. 2001; 8: 31121.
  • 25
    Deinhardt F, Gust ID. Viral hepatitis. Bull. World Health Organ. 1982; 60: 66191.
  • 26
    Kao JH, Chen DS. Global control of hepatitis B virus infection. Lancet Infect. Dis. 2002; 2: 395403.
  • 27
    Ding X, Mizokami M, Yao G et al. Hepatitis B virus genotype distribution among chronic hepatitis B carriers in Shanghai, China. Intervirology 2001; 44: 437.
  • 28
    Thakur V, Guptan RC, Kazim SN, Malhotra V, Sarin SK. Profile, spectrum and significance of HBV genotypes in chronic liver disease patients in the Indian subcontinent. J. Gastroenterol. Hepatol. 2002; 17: 16570.
  • 29
    Chook JB, Yap SF, Tan JA, Rosmawati M. The association between virus genotypes and the development of chronic complications of persistent hepatitis B infection. Med. J. Malaysia 2003; 58: B90.
  • 30
    Liu CJ, Kao JH, Chen PJ, Lai MY, Chen DS. Molecular epidemiology of hepatitis B viral serotypes and genotypes in Taiwan. J. Biomed. Sci. 2002; 9: 16670.
  • 31
    Sun Z, Ming L, Zhu X, Lu J. Prevention and control of hepatitis B in China. J. Med. Virol. 2002; 67: 44750.
  • 32
    Dhir V, Mohandas KM. Epidemiology of digestive tract cancers in India III. Liver. Indian J. Gastroenterol. 1998; 17: 1003.
  • 33
    Sarin SK, Thakur V, Guptan RC et al. Profile of hepatocellular carcinoma in India: an insight into the possible etiologic associations. J. Gastroenterol. Hepatol. 2001; 16: 66673.
  • 34
    Huh K, Choi SY, Whang YS, Lee DS. Prevalence of viral hepatitis markers in Korean patients with hepatocellular carcinoma. J. Korean Med. Sci. 1998; 13: 30610.
  • 35
    Ranjeev P, Rosmawati M, Tan YM, Goh KL. Racial differences in the prevalence of hepatoma in a multiracial south east Asian population. Med. J. Malaysia 1999; 54 (Suppl. 23): D51.
  • 36
    Merican I. Screening for hepatocellular carcinoma. Med. J. Malaysia 1996; 51: 1217.
  • 37
    Abdul Mujeeb S, Jamal Q, Khanani R, Iqbal N, Kaher S. Prevalence of hepatitis B surface antigen and HCV antibodies in hepatocellular carcinoma cases in Karachi, Pakistan. Trop. Doct. 1997; 27: 456.
  • 38
    Chia KS, Seow A, Lee HP, Shanmugaratnam K. Cancer incidence in Singapore 1993−1997. Singapore Cancer Registry Report no. 5. Singapore: Singapore Cancer Registry, 2000.
  • 39
    International Agency for Research on Cancer. Data from Cancer in Thailand 1988–1991. IARC Technical Report no. 16. Lyon: International Agency for Research on Cancer, 1993.
  • 40
    World Health Organization. WHO vaccine-preventable diseases: monitoring system, 2002 global summary. Vaccines and biologicals, December 2002; WHO/V&B/02.20. Cited 5 May 2003. Available from URL:
  • 41
    World Health Organization. Hepatitis B immunization. Introducing Hepatitis B vaccine into national immunization services. Department of Vaccines and Biologicals, October 2001; WHO/V&B/01.28. Cited 5 May 2003. Available from URL:
  • 42
    Poovorawan Y, Theamboonlers A, Vimolket T et al. Impact of hepatitis B immunisation as part of the EPI. Vaccine 2001; 19: 9439.
  • 43
    Lee A, Cheng FF, Chan CS, Lau LC, Lo AS. Sero-epidemiology and risk factors of positive hepatitis B surface antigen amongst Chinese adolescents. Asia Pac. J. Public Health 2001; 13: 305.
  • 44
    Ni YH, Chang MH, Huang LM et al. Hepatitis B virus infection in children and adolescents in a hyperendemic area: 15 years after mass hepatitis B vaccination. Ann. Intern. Med. 2001; 135: 796800.
  • 45
    Lee DH, Kim JH, Nam JJ, Kim HR, Shin HR. Epidemiological findings of hepatitis B infection based on 1998 national health and nutrition survey in Korea. J. Korean Med. Sci. 2002; 17: 45762.
  • 46
    Kao JH, Hsu HM, Shau WY, Chang MH, Chen DS. Universal hepatitis B vaccination and the decreased mortality from fulminant hepatitis in infants in Taiwan. J. Pediatr. 2001; 139: 34952.
  • 47
    Goh KT. Prevention and control of hepatitis B virus infection in Singapore. Ann. Acad. Med. Singapore 1997; 26: 67181.
  • 48
    Consensus statements on the prevention and management of hepatitis B and hepatitis C in the Asia–Pacific region. Core working party for Asia–Pacific consensus on hepatitis B and C. J. Gastroenterol. Hepatol. 2000; 15: 82541.
  • 49
    Liaw YF, Leung N, Guan R et al. Asian–Pacific consensus statement on the management of chronic hepatitis B: an update. J. Gastroenterol. Hepatol. 2003; 18: 23945.
  • 50
    Lok AS, McMahon BJ. Chronic hepatitis B. AASLD practice guidelines. Hepatology 2001; 34: 122541.
  • 51
    Perrillo RP. How will we use the new antiviral agents for hepatitis B? Curr. Gastroenterol. Rep. 2002; 4: 6371.
  • 52
    Liaw YF. Management of  YMDD mutations during lamivudine therapy in patients with chronic hepatitis B. J. Gastroenterol. Hepatol. 2002; 17 (Suppl. 3): S3337.
  • 53
    Brooks EA, Lacey LF, Payne SL, Miller DW. Economic evaluation of lamivudine compared with interferon-α in the treatment of chronic hepatitis B in the United States. Am. J. Manag. Care 2001; 7: 67782.
  • 54
    Leung NW, Lai CL, Chang TT et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 2001; 33: 152732.
  • 55
    Hong SP, Han K-H, Ahn SH et al. Additional lamivudine therapy after HBeAg seroconversion would prolong the durability of response in HBV endemic area. Hepatology 2001; 34: 332A (Abstract 600).
  • 56
    Dienstag JL, Goldin RD, Heathcote EJ et al. Histological outcome during long-term lamivudine therapy. Gastroenterology 2003; 124: 10517.
  • 57
    Leung NW, Lai CL, Guan R, Liaw YF. The effects of longer duration of harbouring lamivudine-resistant hepatitis B virus (YMDD mutants) on liver histology during 3 years lamivudine therapy in Chinese patients. Hepatology 2001; 34: 348A (Abstract 706).